Expression of CD 56 has recently been introduced as one of the adverse prognostic factors
in acute promyelocytic leukemia (APL). However, the clinical significance of CD 56 antigen …

This study investigated the clinical characteristics and prognostic relevance of CD34
expression in 47 patients with acute promyelocytic leukemia (APL), showing t (15; 17) or …

The biological significance of CD56 antigen expression in patients with acute promyelocytic
leukemia (APL) has been under investigation. We investigated the clinical and biologic …

Potential clinical significance of CD34 expression in acute promyelocitic leukemia (APL) has
not been deeply investigated. We hereby analyzed the clinico-biological features and …

PURPOSE: Blast expression of CD56 is frequent in patients with t (8; 21)(q22; q22) acute
myeloid leukemia and is associated with an inferior outcome. The expression of CD56 has …

The expression of CD56 antigen in acute promyelocytic leukemia (APL) blasts has been
associated with short remission duration and extramedullary relapse. We investigated the …

Acute promyelocytic leukemia (APL) has a favorable prognosis. Current therapy includes
chemotherapy used in combination with all‐trans‐retinoic acid (ATRA). Although the …

We aimed to explore the expression of CD34 and its impact on the disease outcome in
patients with APL. The study comprised 40 de novo APL patients. Diagnostic tools included …

Limited information is available on the relationship between expression of some additional
aberrant phenotypic features and outcome of acute promyelocytic leukemia (APL) patients …

PURPOSE: Preliminary reports suggest that leukemic cell expression of CD56, a neural cell
adhesion molecule, is associated with adverse clinical outcome in either acute myeloid …